A Study of STAR-0215 in Participants With Hereditary Angioedema

Overview

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and the other group will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

Full Title of Study: “A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants With Hereditary Angioedema (The ALPHA-STAR Trial)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2024

Detailed Description

This is a Phase 1b/2 single and multiple dose trial evaluating the safety, tolerability, clinical activity, pharmacokinetics, pharmacodynamics, and immunogenicity of subcutaneous administration of STAR-0215 in participants with type I or type II HAE in 2 dose cohorts. The first cohort will receive 1 dose of STAR-0215; the second cohort will receive 2 sequential doses. This is the first trial of STAR-0215 in participants with HAE and the first evaluation of a multiple-dose regimen.

Interventions

  • Drug: STAR-0215
    • STAR-0215 will be administered as a subcutaneous bolus injection.

Arms, Groups and Cohorts

  • Experimental: Cohort 1 – Single Dose
    • Participants will receive 1 dose of STAR-0215.
  • Experimental: Cohort 2 – Multiple Dose
    • Participants will receive 2 doses of STAR-0215 administered 3 months apart.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants Experiencing Treatment-emergent Adverse Events
    • Time Frame: Day 1 through Day 168 (Cohort 1) and Day 251 (Cohort2)

Secondary Measures

  • Change From Baseline In Monthly HAE Attack Rate
    • Time Frame: Baseline through Day 168 (Cohort 1) and Day 251 (Cohort 2)
  • Severity Of HAE Attacks Experienced By Participants
    • Time Frame: Cohort 1: Day 1 through Day 168; Cohort 2: Day 1 through Day 251
    • All HAE attacks will be classified according to severity (mild, moderate, and severe).
  • Duration Of HAE Attacks
    • Time Frame: Cohort 1: Day 1 through Day 168; Cohort 2: Day 1 through Day 251
    • Duration will be reported as shorter than 12 hours, 12 to 24 hours, 24 to 48 hours, and longer than 48 hours.
  • Number of Participants Experiencing HAE Attacks Requiring On-demand Therapy
    • Time Frame: Cohort 1: Day 1 through Day 168; Cohort 2: Day 1 through Day 251
  • Time To First HAE Attack After First And Last Dosing
    • Time Frame: Cohort 1: Day 1 through Day 168; Cohort 2: Day 1 through Day 251
  • Serum Concentration Of STAR-0215
    • Time Frame: Cohort 1: Day 1 (pre-infusion, up to 4 hours post dose); Days 2, 7, 14, 28, 56, 84, 112, 140, and 168; Cohort 2: Days 1 and 84 (pre-infusion, up to 4 hours post dose); Days 2, 7, 14, 28, 56, 85, 90, 97, 111, 139, 167, 209, and 251
    • Blood samples will be collected to measure the serum concentration of STAR-0215 before and after study drug administration.
  • Plasma Levels Of Cleaved High-molecular-weight Kininogen
    • Time Frame: Cohort 1: Day 1 (pre-infusion, up to 4 hours post dose); Days 2, 7, 14, 28, 56, 84, 112, 140, and 168; Cohort 2: Days 1 and 84 (pre-infusion, up to 4 hours post dose); Days 2, 7, 14, 28, 56, 85, 90, 97, 111, 139, 167, 209, and 251
    • Blood samples will be collected to measure the plasma levels of cleaved high-molecular-weight kininogen (a measure of plasma kallikrein activity).
  • Number Of Participants With Anti-drug Antibodies To STAR-0215
    • Time Frame: Cohort 1: Day 1 (pre-infusion); Days 14, 28, 56, 84, 112, 140, and 168; Cohort 2: Days 1 and 84 (pre-infusion); Days 14, 28, 56, 111, 167, and 251
    • Blood samples will be collected to assess the formation of STAR-0215 anti-drug antibodies in serum before and after study drug administration.

Participating in This Clinical Trial

Inclusion Criteria

1. Documented diagnosis of HAE (type I or II). The following must be met: a. Documented clinical history consistent with HAE (for example, subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria). 2. Experienced at least 4 HAE attacks within the 12 months prior to Screening, per participant report. 3. Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack. Exclusion Criteria:

1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria. 2. Use of therapies prescribed for the prevention of HAE attacks prior to Screening: 1. lanadelumab within 90 days 2. berotralstat within 21 days 3. all other prophylactic therapies, within 7 days 3. Any exposure to angiotensin-converting enzyme inhibitors or any estrogen containing medications with systemic absorption (such as hormonal contraceptives or hormone replacement therapy) within 28 days prior to Screening. 4. Any exposure to androgens (for example, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within 7 days prior to Screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Astria Therapeutics, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Christopher Morabito, MD, 1-617-349-1971, cmorabito@astriatx.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.